Elanco Animal Health Incorporated (NYSE:ELAN) Position Lowered by Jacobi Capital Management LLC

Jacobi Capital Management LLC decreased its stake in shares of Elanco Animal Health Incorporated (NYSE:ELANGet Rating) by 32.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,591 shares of the company’s stock after selling 7,079 shares during the period. Jacobi Capital Management LLC’s holdings in Elanco Animal Health were worth $381,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. DAVENPORT & Co LLC lifted its holdings in Elanco Animal Health by 9.2% in the first quarter. DAVENPORT & Co LLC now owns 22,407 shares of the company’s stock worth $585,000 after acquiring an additional 1,885 shares during the last quarter. 1832 Asset Management L.P. lifted its holdings in Elanco Animal Health by 11.3% in the fourth quarter. 1832 Asset Management L.P. now owns 1,484,650 shares of the company’s stock worth $42,964,000 after acquiring an additional 150,462 shares during the last quarter. Resonant Capital Advisors LLC lifted its holdings in Elanco Animal Health by 4.5% in the first quarter. Resonant Capital Advisors LLC now owns 14,294 shares of the company’s stock worth $373,000 after acquiring an additional 614 shares during the last quarter. New York State Common Retirement Fund lifted its holdings in Elanco Animal Health by 11.0% in the fourth quarter. New York State Common Retirement Fund now owns 760,061 shares of the company’s stock worth $21,571,000 after acquiring an additional 75,573 shares during the last quarter. Finally, Allianz Asset Management GmbH lifted its holdings in Elanco Animal Health by 20.9% in the fourth quarter. Allianz Asset Management GmbH now owns 1,101,427 shares of the company’s stock worth $31,258,000 after acquiring an additional 190,114 shares during the last quarter.

Elanco Animal Health Trading Up 2.2 %

NYSE ELAN opened at $19.44 on Friday. Elanco Animal Health Incorporated has a 12 month low of $18.64 and a 12 month high of $35.69. The company has a current ratio of 2.44, a quick ratio of 1.41 and a debt-to-equity ratio of 0.80. The company’s 50 day simple moving average is $20.98 and its 200 day simple moving average is $24.04.

Elanco Animal Health (NYSE:ELANGet Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.01. Elanco Animal Health had a negative net margin of 7.65% and a positive return on equity of 6.61%. The business had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same quarter last year, the business earned $0.37 earnings per share. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. On average, analysts anticipate that Elanco Animal Health Incorporated will post 1.15 EPS for the current year.

Analyst Ratings Changes

ELAN has been the topic of several analyst reports. Morgan Stanley dropped their price target on shares of Elanco Animal Health to $37.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 17th. Piper Sandler initiated coverage on shares of Elanco Animal Health in a research note on Monday, July 11th. They issued a “neutral” rating and a $22.00 price target on the stock. The Goldman Sachs Group lowered shares of Elanco Animal Health from a “buy” rating to a “sell” rating and dropped their price target for the company from $32.00 to $19.00 in a research note on Thursday, July 21st. Finally, Stifel Nicolaus dropped their price target on shares of Elanco Animal Health from $30.00 to $22.00 and set a “hold” rating on the stock in a research note on Friday, June 24th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $26.40.

Insider Activity at Elanco Animal Health

In related news, Director R David Hoover acquired 10,000 shares of the stock in a transaction that occurred on Friday, May 20th. The shares were acquired at an average price of $23.33 per share, for a total transaction of $233,300.00. Following the completion of the purchase, the director now directly owns 125,000 shares of the company’s stock, valued at $2,916,250. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 6.40% of the company’s stock.

Elanco Animal Health Profile

(Get Rating)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

See Also

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.